Get informed when a big investor buys or sells
+ FollowOctober 22, 2026 - AI Summary
Overvalued by 100.2% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $241.59 Billion |
|---|---|
| Enterprise Value | $243.93 Billion |
| Annual dividend | $0.08 |
| Dividend yield | 0.31% |
| Earnings per Share | $0.03 |
| Beta | 1.14 |
| Outstanding Shares | 9,729,641,900 |
| P/E Ratio | 66.83 |
|---|---|
| PEG | 145.48 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 79.63 |
| Enterprise Value to EBIT | 214.45 |
| Enterprise Value to Net Income | 775 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.57 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Sartorius Stedim Biotech S.A., a global entity and a subsidiary of Sartorius AG, delivers critical instruments, consumables, and services tailored for the biopharmaceutical industry. Their extensive product portfolio includes fundamental...